BioCardia announced that Japan’s Pharmaceutical and Medical Device Agency (PMDA) has given a positive consultation regarding its CardiAMP cell therapy for treating ischemic heart failure. This condition occurs when the heart can’t pump enough blood due to reduced ejection fraction, which is a measure of how well the heart is working. The PMDA’s support comes after BioCardia completed three clinical trials, indicating that the therapy could be a viable option for around 20,000 of the 300,000 patients in Japan who have elevated levels of NTproBNP and are currently on stable medical therapy.

This development is significant for people with heart issues, particularly those who have not responded well to existing treatments. If approved, CardiAMP could offer a new avenue for improving heart function and overall quality of life. The therapy aims to enhance heart muscle recovery, potentially leading to better energy levels and a reduction in heart-related complications.

However, it’s important to note that this is still in the early stages of regulatory approval. The PMDA has requested further evidence to ensure that patients are on the appropriate medical therapy and not candidates for other interventions like surgery. BioCardia plans to submit its application within the next seven months, during which it will also work on post-market studies to ensure the therapy’s safe and effective use.

For those interested in heart health, staying informed about new therapies like CardiAMP could be crucial. Engaging with healthcare providers about emerging treatments and maintaining a heart-healthy lifestyle can help manage heart health effectively.

Source: longevity.technology